Curaleaf HoldingsCURLF -0.53%67 Debt-to-Equity is 1.02 as of Mar. 2026, which is 70% above its 10-year median of 0.60. GuruFocus rates CURLF with a GF Score™ of 67/100 and a GF Value™ of $7.98 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 810 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 85.93% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Curaleaf Holdings's Debt-to-Equity or its related term are showing as below:
CURLF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.6 Max: 1.18
Current: 1.02
During the past 12 years, the highest Debt-to-Equity Ratio of Curaleaf Holdings was 1.18. The lowest was 0.10. And the median was 0.60.
CURLF's Debt-to-Equity is ranked worse than 85.93% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs CURLF: 1.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Curaleaf Holdings Debt-to-Equity Related Terms
Curaleaf Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (CURLF) has a Debt-to-Equity of 1.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Curaleaf Holdings and its competitors. This is 70% above median its historical median of 0.60. Over the past decade, Curaleaf Holdings' Debt-to-Equity has ranged from 0.10 to 1.18. According to the industry distribution chart, Curaleaf Holdings ranks #696 out of 810 companies in the Drug Manufacturers industry, placing it in the top 85.9%.
Is Curaleaf Holdings' Debt-to-Equity too high?
Curaleaf Holdings' current Debt-to-Equity of 1.02 is 70% above median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.18. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Curaleaf Holdings' value of 1.02 is 277.8% above this industry median. Based on the distribution chart, Curaleaf Holdings ranks #696 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curaleaf Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #696 out of 810 companies for Debt-to-Equity. This places Curaleaf Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Curaleaf Holdings' value of 1.02 is 277.8% above this benchmark. Historically, Curaleaf Holdings' own Debt-to-Equity has ranged from 0.10 to 1.18 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 0.27, Curaleaf Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Debt-to-Equity of 1.02 is 277.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Debt-to-Equity is 1.02, which is 70% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.98, compared to a current price of $9.35 — trading 17.2% above its estimated fair value. The current Debt-to-Equity is 1.02, which is 70% above median its 10-year median of 0.60 and 277.8% above the Drug Manufacturers industry median of 0.27. Curaleaf Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Debt-to-Equity is 1.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.35 is trading 17.2% above its estimated GF Value™ of $7.98.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Debt-to-Equity: 1.02 (70% above median its 10-year median of 0.60)
GF Value™: $7.98 vs. price of $9.35 (17.2% above fair value)
Industry Position: 277.8% above the Drug Manufacturers median (#696 of 810)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
67GF Score
Get the complete analysis for CURLF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
